NCT04009681 2025-12-15
HAMMER
Synthorx, Inc, a Sanofi company
Phase 1/2 Terminated
Clinical Trials
12 trialsNCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT03887442 2021-01-07
EXTAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 2 Terminated
NCT01488318 2018-01-05
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
University of Pittsburgh
Phase 2 Terminated
NCT02316496 2017-08-01
REGAIN
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Terminated
NCT00537823 2016-12-20
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
Washington University School of Medicine
Phase 2 Terminated
NCT01074333 2014-06-17
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
Merck KGaA, Darmstadt, Germany
Terminated
NCT01360827 2014-06-17
EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Merck KGaA, Darmstadt, Germany
Phase 1 Terminated
NCT00719199 2013-10-22
Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer
EMD Serono
Phase 1 Terminated
NCT00908024 2013-06-18
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT00327093 2009-02-09
Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
Hospices Civils de Lyon
Phase 4 Terminated